Phathom Pharmaceuticals annual operating cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Phathom Pharmaceuticals Operating Cash Flow Growth & History (PHAT)
Phathom Pharmaceuticals's operating cash flow was −$166.8M for fiscal 2025.
View full Phathom Pharmaceuticals company overviewPhathom Pharmaceuticals annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$166.8M | $100.0M | — |
| 2024 | 2024-12-31 | −$266.8M | −$129.2M | — |
| 2023 | 2023-12-31 | −$137.6M | $8.9M | — |
| 2022 | 2022-12-31 | −$146.5M | $1.9M | — |
| 2021 | 2021-12-31 | −$148.5M | −$78.8M | — |
| 2020 | 2020-12-31 | −$69.7M | −$33.2M | — |
| 2019 | 2019-12-31 | −$36.5M | −$35.5M | — |
| 2018 | 2018-12-31 | −$1.0M | — | — |
Phathom Pharmaceuticals quarterly operating cash flow
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$1.9M | $60.8M | — |
| Q1 2026 | 2026-03-31 | −$15.6M | $69.3M | — |
| Q4 2025 | 2025-12-31 | −$5.0M | $58.5M | — |
| Q3 2025 | 2025-09-30 | −$14.1M | $49.5M | — |
| Q2 2025 | 2025-06-30 | −$62.7M | $8.0M | — |
| Q1 2025 | 2025-03-31 | −$84.9M | −$15.9M | — |
| Q4 2024 | 2024-12-31 | −$63.5M | −$19.7M | — |
| Q3 2024 | 2024-09-30 | −$63.6M | −$31.7M | — |
| Q2 2024 | 2024-06-30 | −$70.7M | −$48.5M | — |
| Q1 2024 | 2024-03-31 | −$69.0M | −$29.4M | — |
| Q4 2023 | 2023-12-31 | −$43.8M | −$2.8M | — |
| Q3 2023 | 2023-09-30 | −$31.9M | $3.1M | — |
| Q2 2023 | 2023-06-30 | −$22.2M | $3.5M | — |
| Q1 2023 | 2023-03-31 | −$39.7M | $5.1M | — |
| Q4 2022 | 2022-12-31 | −$41.0M | $221,000 | — |
| Q3 2022 | 2022-09-30 | −$35.0M | −$6.0M | — |
| Q2 2022 | 2022-06-30 | −$25.7M | $2.6M | — |
| Q1 2022 | 2022-03-31 | −$44.8M | $5.0M | — |
| Q4 2021 | 2021-12-31 | −$41.3M | −$13.1M | — |
| Q3 2021 | 2021-09-30 | −$29.1M | −$8.3M | — |
| Q2 2021 | 2021-06-30 | −$28.4M | −$19.0M | — |
| Q1 2021 | 2021-03-31 | −$49.8M | −$38.3M | — |
| Q4 2020 | 2020-12-31 | −$28.2M | −$4.8M | — |
| Q3 2020 | 2020-09-30 | −$20.7M | −$13.6M | — |
| Q2 2020 | 2020-06-30 | −$9.3M | −$4.1M | — |
| Q1 2020 | 2020-03-31 | −$11.4M | −$10.6M | — |
| Q4 2019 | 2019-12-31 | −$23.4M | — | — |
| Q3 2019 | 2019-09-30 | −$7.1M | — | — |
| Q2 2019 | 2019-06-30 | −$5.2M | — | — |
| Q1 2019 | 2019-03-31 | −$807,000 | — | — |
Phathom Pharmaceuticals operating cash flow trends
Over the last five fiscal years, Phathom Pharmaceuticals's operating cash flow decreased from −$69.7M to −$166.8M, a change of −$97.1M. The latest reported quarter, Q2 2026, shows −$1.9M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Phathom Pharmaceuticals source filings ↗Community posts
Phathom’s Voquezna growth narrows its quarterly loss and supports positive operating cash flow
Phathom Pharmaceuticals ($PHAT) reported third-quarter 2026 revenue of $84.7 million, up 71% from a year earlier and 14% from the preceding quarter. Cumulative Voquezna prescriptions surpassed two million, reflecting continued adoption of t ...
Phathom’s Voquezna exclusivity dispute expands with FDA consultation and another challenger
Phathom ($PHAT) said the FDA opened a public docket seeking comment on legal and regulatory questions raised by a challenge to Voquezna’s exclusivity. Comments are due by November 23. Phathom has also moved to intervene in BDR Pharmaceutica ...
